Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 33798493

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2021 May
First author
Lamarca A

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Jul;22(7):e284. doi: 10.1016/S1470-2045(21)00211-4.
    note
    Source null
    related pmid
    34197747
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2021 Jul;22(7):e285. doi: 10.1016/S1470-2045(21)00243-6.
    note
    Source null
    related pmid
    34197748
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2021 Jul;22(7):e286. doi: 10.1016/S1470-2045(21)00269-2.
    note
    Source null
    related pmid
    34197749
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2021 Jul;22(7):e287. doi: 10.1016/S1470-2045(21)00280-1.
    note
    Source null
    related pmid
    34197750
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2021 Jul;22(7):e288-e289. doi: 10.1016/S1470-2045(21)00341-7.
    note
    Source null
    related pmid
    34197751
    relationship
    Comment in

Authors and identifiers

  1. name
    Lamarca A
    type
    Author
  2. name
    Palmer DH
    type
    Author
  3. name
    Wasan HS
    type
    Author
  4. name
    Ross PJ
    type
    Author
  5. name
    Ma YT
    type
    Author
  6. name
    Arora A
    type
    Author
  7. name
    Falk S
    type
    Author
  8. name
    Gillmore R
    type
    Author
  9. name
    Wadsley J
    type
    Author
  10. name
    Patel K
    type
    Author
  11. name
    Anthoney A
    type
    Author
  12. name
    Maraveyas A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Lamarca A
    type
    Author
  2. name
    Palmer DH
    type
    Author
  3. name
    Wasan HS
    type
    Author
  4. name
    Ross PJ
    type
    Author
  5. name
    Ma YT
    type
    Author
  6. name
    Arora A
    type
    Author
  7. name
    Falk S
    type
    Author
  8. name
    Gillmore R
    type
    Author
  9. name
    Wadsley J
    type
    Author
  10. name
    Patel K
    type
    Author
  11. name
    Anthoney A
    type
    Author
  12. name
    Maraveyas A
    type
    Author
bibliography ids
  1. nci-bib-7951ec11c9753196b0765386
book metadata
content sha256
a987b165b0b37ac9ecdd0878ee6364d2beba0290a82570c9bb3782ccec16c9cb
document type
citation
dois
  1. 10.1016/S1470-2045(21)00027-9
electronic publication date
display
2021 Mar 30
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:33798493
immutable id
pubmed:33798493@a987b165b0b37ac9ecdd0878ee6364d2beba0290a82570c9bb3782ccec16c9cb
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
5
name
The Lancet. Oncology
nlm unique id
100957246
pages
690-701
volume
22
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Jul;22(7):e284. doi: 10.1016/S1470-2045(21)00211-4.
    note
    Source null
    related pmid
    34197747
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2021 Jul;22(7):e285. doi: 10.1016/S1470-2045(21)00243-6.
    note
    Source null
    related pmid
    34197748
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2021 Jul;22(7):e286. doi: 10.1016/S1470-2045(21)00269-2.
    note
    Source null
    related pmid
    34197749
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2021 Jul;22(7):e287. doi: 10.1016/S1470-2045(21)00280-1.
    note
    Source null
    related pmid
    34197750
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2021 Jul;22(7):e288-e289. doi: 10.1016/S1470-2045(21)00341-7.
    note
    Source null
    related pmid
    34197751
    relationship
    Comment in
outcomes validated
false
pmid
33798493
provenance
batch id
79f1021053e858d13ff3
provider
NCBI PubMed ESummary
record sha256
4b37208a6e711722576c74adff4aebdc934e7ed266c1cc34de52f483710392c1
response sha256
671d3d2962f73c698a1cb338d73222e2cc6cfdf61569f91b42612d5b59822e05
retrieved at
2026-09-09T23:47:59.098265+00:00
publication date
display
2021 May
precision
month
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/33798493/
title
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.

Preserved source evidence · Not medical advice